CClinicalTrials.gg
Sign In
RecruitingNCT07499934EMIPUpdated Mar 30, 2026

Experience of UHR and PEP Individuals During Mindfulness: a Qualitative Phenomenological Study

An interventional study of Qualitative interview in Clinical High Risk for Psychosis (CHR), sponsored by Centre Psychothérapique de Nancy. Recruiting at 2 sites in France. Open to participants aged 15 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-03-30.

Sponsored by Centre Psychothérapique de Nancy · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Jan 2026; still recruiting 8 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
15 Years to 30 Years
Sex
All
01

Study summary

The goal of this qualitative study is to explore and describe the lived experiences of individuals at ultra-high risk (UHR) or first episode of psychosis (FEP) who have participated in a group-based mindfulness-based intervention. Secondary objectives include identifying potential adverse effects of a group-based mindfulness-based intervention among UHR or FEP.

02

Conditions studied

  • Clinical High Risk for Psychosis (CHR)

Browse trials for

Keywords

  • Psychosis
  • mindfulness
03

In context

Psychotic Disorders

1,626 studies on the registry are indexed under Psychotic Disorders; 293 are open to participants now.

This study's planned enrollment of 20 is below the median of 70 across 1,333 interventional studies indexed under Psychotic Disorders.

Browse Psychotic Disorders studies →

Lead sponsor

Centre Psychothérapique de Nancy is the lead sponsor of 19 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • People aged between 15 and 30 years who meet the criteria for UHR or PEP status on the CAARMS scale and have a social functional impact (SOFAS score less than 50 or a decrease of more than 30% in the score)

Exclusion criteria

Exclusion Criteria:

  • - Previous episode of schizophrenia, schizoaffective disorder, or bipolar disorder
  • Previous antipsychotic treatment for more than 12 months
  • Organic mental disorder or intellectual disability
  • Serious suicide/homicidal risk (but admissible if this risk has been resolved)
  • Insufficient French language skills
  • Adult unable to give consent and not under legal guardianship
  • Protective measure (guardianship/conservatorship/judicial protection) or under judicial supervision
  • Person deprived of liberty by judicial or administrative decision (including actual involuntary hospitalization)
  • Persons in a life-threatening emergency
  • Not affiliated with a social security scheme
  • Minors without parental authorization
  • Person who refused the audio recording of the interview
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Other
    Qualitative interview

    qualitative interview

    Other: Qualitative interview

Interventions

  • OtherQualitative interview

    analysis of interview data using the IPSE (Inductive Process to analyze the Structure of lived Experience) method

06

What researchers measure

Primary outcomes

  1. Lived experiences

    To explore and describe the lived experiences of individuals with UHR or FEP who have participated in a group-based mindfulness intervention using the IPSE method.

    Time frame: The qualitative interview takes place between one week and three months after the final session of the mindfulness-based program

07

Study locations

2 of 2 sites recruiting
  • Centre Psychothérapique de Nancy
    Laxou, 54520, France
    Recruiting
  • Clinique Fondation Santé des Etudiants de France
    Vitry-le-François, France
    • Tatiana ONEA, MD · Contact · tatiana.onea@fsef.net · 01 45 89 43 39
    • Tatiana ONEA, MD · Principal investigator
    Recruiting
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07499934
Lead sponsor
Centre Psychothérapique de Nancy
Responsible party
Sponsor
First posted
Mar 30, 2026
Start date
Jan 19, 2026
Primary completion
Jan 19, 2027 (estimated)
Completion
Jul 19, 2027 (estimated)
Last update
Mar 30, 2026

Study contacts

William DALFIN, MD
Contact
william.dalfin@cpn-laxou.com
+33 3 83 92 68 22
Naoual MELLOUKI BENDIMRED, PhD
Contact
unic@cpn-laxou.com
0383925267 ext. 33
william DALFIN
principal investigator · Centre Psychothérapique de Nancy

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Psychotic Disorders→

Other studies from this sponsor

Centre Psychothérapique de Nancy

Start the discussion